Site-specific molecular design and its relevance to pharmacogenomics and chemical biology

Pharmacogenomics Journal

Volumn 1, Issue 1, 2001, Pages 38-47

  Bailey, D ^a  

^a De Novo Pharmaceuticals   (United Kingdom)

Author keywords

Chemical genomics; Computational chemistry; Drug design; Pharmacogenomlcs; Structural genomics

Indexed keywords

LIGAND; PROTEOME;

ARTICLE; BINDING SITE; BIOLOGY; COMPUTER AIDED DESIGN; CONFORMATION; DRUG DESIGN; GENOME; HUMAN; PHARMACOGENETICS;

BINDING SITES; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; DRUG DESIGN; GENOME; HUMANS; LIGANDS; MOLECULAR CONFORMATION; PHARMACOGENETICS; PROTEOME;

EID: 0035752193     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500004     Document Type: Article

References (5)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton CC et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
2. Blake JF. Chemoinformatics-predicting the physicochemical properties of 'drug-like' molecules. Curr Opin Biotechnol 2000; 1: 104-107.
3. Bailey DS, Bondar A, Furness ML. Pharmacogenomics-it's not just pharmacogenetics. Curr Opin Biotech 1998; 9: 595-601.
4. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nature Rev2000; 1: 116-125.
5. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.